Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
Saved in:
| Title: | Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. |
|---|---|
| Authors: | Sayed NH; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Fathy N; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. nevine.abdallah@pharma.cu.edu.eg., Kortam MA; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Rabie MA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Mohamed AF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt., Kamel AS; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. |
| Source: | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [Neurotherapeutics] 2022 Mar; Vol. 19 (2), pp. 686. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics Country of Publication: United States NLM ID: 101290381 Publication Model: Print Cited Medium: Internet ISSN: 1878-7479 (Electronic) Linking ISSN: 18787479 NLM ISO Abbreviation: Neurotherapeutics Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1878-7479 |
|---|---|
| DOI: | 10.1007/s13311-022-01227-6 |
